News - Human Genome Sciences


Current filters:

Human Genome Sciences

Popular Filters

GlaxoSmithKline goes on attack over Human Genome bid


UK pharma giant GlaxoSmithKline (LSE: GSK) went into attack mode this morning, taking its unsolicited…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceutical

Benlysta continues to penetrate lupus market one year post-launch; report


More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

GSK takeover target Human Genome sees 4th-qtr loss narrow


Human Genome Sciences (Nasdaq: HGSI), the subject of a $2.59 billion hostile takeover bid from the UK's…

BenlystaBiotechnologyFinancialHuman Genome Sciences

Human Genome rejects unsolicited takeover bid from GlaxoSmithKline


US drugmaker Human Genome Sciences (Nasdaq: HGSI) revealed yesterday that it has rejected an unsolicited…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Ph III albiglutide data in type 2 diabetes supports move to filing, says GSK


UK pharma giant GlaxoSmithKline plc (LSE: GSK) says that top-line results have been received from seven…

albiglutideDiabetesGlaxoSmithKlineHuman Genome SciencesPharmaceuticalResearch

Human Genome Sciences’ Benlysta sales disappoint


US biotech firm Human Genome Sciences (Nasdaq: HGSI) president and chief executive Thomas Watkins yesterday…

BenlystaBiotechnologyFinancialHuman Genome SciencesMarkets & MarketingRare diseasesraxibacumab

Benlysta gaining bigger US market share


Over half of surveyed US rheumatologists surveyed by Decision Resources unit BioTrends have initiated…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingNorth AmericaPharmaceuticalRare diseases

Systemic lupus erythematosus drug market to grow to $1.6 billion in 2018


The global systemic lupus erythematosus (SLE) therapeutics market in the seven leading countries ( the…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineGlobalHuman Genome SciencesMarkets & MarketingPharmaceutical

Important decision for the biotech industry from UK Supreme Court


The UK’s Supreme Court yesterday gave guidance on the patentability of gene sequence inventions,…

BenlystaBiotechnologyEli LillyEuropeGlaxoSmithKlineHuman Genome SciencesLegalPatentsPharmaceutical

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports


Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Human Genome Sciences names senior VP; Avanir appoints R&D chief


USA-based Human Genome Sciences (Nasdaq: HSGI) says that Craig Parker has joined the company as senior…

Avanir PharmaceuticalsBiotechnologyHuman Genome SciencesManagementPharmaceutical

Benlysta heading in right direction, but uptake slower than originally expected, says BioTrends


Rheumatologists are maintaining enthusiasm for Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceutical

Back to top